BR112014013374A8 - Comprimidos de acamprosato e usos de acamprosato - Google Patents

Comprimidos de acamprosato e usos de acamprosato

Info

Publication number
BR112014013374A8
BR112014013374A8 BR112014013374A BR112014013374A BR112014013374A8 BR 112014013374 A8 BR112014013374 A8 BR 112014013374A8 BR 112014013374 A BR112014013374 A BR 112014013374A BR 112014013374 A BR112014013374 A BR 112014013374A BR 112014013374 A8 BR112014013374 A8 BR 112014013374A8
Authority
BR
Brazil
Prior art keywords
acamprosate
formulations
pills
methods
drug
Prior art date
Application number
BR112014013374A
Other languages
English (en)
Other versions
BR112014013374B1 (pt
BR112014013374A2 (pt
Inventor
S Fogel Barry
David Wong
Edward Lin
Kei-Lai Fong
San-Laung Chow
D Kerns William
Original Assignee
Synchroneuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synchroneuron Inc filed Critical Synchroneuron Inc
Publication of BR112014013374A2 publication Critical patent/BR112014013374A2/pt
Publication of BR112014013374A8 publication Critical patent/BR112014013374A8/pt
Publication of BR112014013374B1 publication Critical patent/BR112014013374B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulações de acamprosato, métodos de usar as mesmas, e combinações compreendendo as mesmas. modalidades aqui divulgadas, geralmente, referem-se às formulações de acamprosato, métodos de utilização das formulações, aos métodos de utilização das formulações em combinação com pelo menos outro medicamento, e para produtos de combinação e as composições que compreendem as formulações e pelo menos outro medicamento, tal como neuroléptico (antipsicótico) e/ou fármacos antidepressivos.
BR112014013374-3A 2011-12-02 2012-12-02 Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados BR112014013374B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161566550P 2011-12-02 2011-12-02
US61/566,550 2011-12-02
US201261649137P 2012-05-18 2012-05-18
US61/649,137 2012-05-18
PCT/US2012/067507 WO2013082573A1 (en) 2011-12-02 2012-12-02 Acamprosate formulations, methods of using the same, and combinations comprising the same

Publications (3)

Publication Number Publication Date
BR112014013374A2 BR112014013374A2 (pt) 2017-06-13
BR112014013374A8 true BR112014013374A8 (pt) 2021-08-31
BR112014013374B1 BR112014013374B1 (pt) 2022-10-11

Family

ID=48536156

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013374-3A BR112014013374B1 (pt) 2011-12-02 2012-12-02 Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados

Country Status (14)

Country Link
EP (1) EP2785337B1 (pt)
JP (1) JP6407720B2 (pt)
KR (1) KR102055859B1 (pt)
CN (1) CN104379138B (pt)
AU (1) AU2012345659B2 (pt)
BR (1) BR112014013374B1 (pt)
CA (1) CA2863265C (pt)
HK (2) HK1199841A1 (pt)
IL (1) IL232935B (pt)
MX (1) MX2014006574A (pt)
RU (1) RU2671399C2 (pt)
SG (1) SG11201403785UA (pt)
WO (1) WO2013082573A1 (pt)
ZA (1) ZA201404826B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
JP2016520653A (ja) * 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
WO2020206107A1 (en) * 2019-04-03 2020-10-08 Synchroneuron Inc. Formulations
MX2022003925A (es) * 2019-10-11 2022-04-20 Hoffmann La Roche Dispositivos y metodos de determinacion de la dosis del farmaco.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU765522B2 (en) * 1998-01-13 2003-09-18 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
MXPA04010956A (es) * 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
RU2284814C1 (ru) * 2005-04-08 2006-10-10 Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" Способ лечения оптического неврита при оптикохиазмальном арахноидите в стадии ремиссии
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2428204A3 (en) * 2006-12-07 2012-07-04 Schering Corporation pH sensitive matrix formulation
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
WO2011102506A1 (ja) * 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
CN101987081B (zh) * 2010-07-16 2012-08-08 钟术光 一种控释制剂
US9000046B2 (en) * 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract

Also Published As

Publication number Publication date
BR112014013374B1 (pt) 2022-10-11
EP2785337B1 (en) 2021-01-20
IL232935A0 (en) 2014-07-31
CA2863265A1 (en) 2013-06-06
AU2012345659B2 (en) 2017-09-28
RU2671399C2 (ru) 2018-10-31
BR112014013374A2 (pt) 2017-06-13
HK1199841A1 (en) 2015-07-24
EP2785337A4 (en) 2015-04-22
EP2785337A1 (en) 2014-10-08
KR20140121394A (ko) 2014-10-15
MX2014006574A (es) 2015-02-10
JP6407720B2 (ja) 2018-10-17
SG11201403785UA (en) 2014-10-30
WO2013082573A1 (en) 2013-06-06
IL232935B (en) 2020-11-30
KR102055859B1 (ko) 2019-12-13
AU2012345659A8 (en) 2014-08-07
ZA201404826B (en) 2016-07-27
CN104379138A (zh) 2015-02-25
HK1207563A1 (en) 2016-02-05
JP2015500812A (ja) 2015-01-08
AU2012345659A1 (en) 2014-07-24
CA2863265C (en) 2020-04-14
RU2014126879A (ru) 2016-01-27
CN104379138B (zh) 2021-12-07

Similar Documents

Publication Publication Date Title
MX2016008448A (es) Conjugados de var2csa-farmaco.
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112015032432A2 (pt) Conjugado de oligonucleotídeo antisense, oligômero, composição farmacêutica, uso de um oligômero ou conjugado de oligonucleotídeo antisense ou composição farmacêutica, método de tratamento da hipercolesterolemia ou de distúrbios relacionados e método in vivo ou in vitro
CL2014002983A1 (es) Compuestos derivados de 1h-pirazolo[3,4-b]piridina, como inhibidores de una o mas proteinas en la ruta de wnt; composicion farmaceutica que los comprende, util para el tratamiento de cancer, retinopatia diabetica, fibrosis pulmonar, artritis reumatoide, enfermedad de alzheimer, entre otras.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112015027321A8 (pt) Compostos e composições para modular a expressão de apolipoproteína(a) e seus usos
BR112014003919A2 (pt) métodos e meios para modificar um genoma de planta
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
BR112015011118A2 (pt) conjugado; composição farmacêutica; e uso de um ou mais dos conjugados
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35210A (es) Inhibidores de autotaxina
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
BR112013003004A2 (pt) processos para a preparação de tubulisinas
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
BR112013001613A2 (pt) compostos tricíclicos e métodos para fazer e usar os mesmos.
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
PE20140255A1 (es) Tableta dispersable en forma oral
BR112017016503A2 (pt) conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
BR102013022698B8 (pt) Éster de poliglicerol, processo para a produção do mesmo, seu uso e formulação cosmética ou farmacêutica
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 31/185 , A61K 9/20 , A61K 9/48 , A61P 25/00

Ipc: A61K 31/185 (2006.01), A61K 45/06 (2006.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2012, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2701 DE 11/10/2022, QUANTO AO ITEM (54) TITULO.